4,516 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,516 shares of the biopharmaceutical company's stock, valued at approximately $1,063,000.

Several other institutional investors also recently modified their holdings of ALNY. Allspring Global Investments Holdings LLC increased its holdings in Alnylam Pharmaceuticals by 62.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company's stock worth $116,000 after purchasing an additional 161 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Alnylam Pharmaceuticals by 56.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 6,454 shares of the biopharmaceutical company's stock worth $1,775,000 after purchasing an additional 2,323 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 41.4% in the third quarter. Nisa Investment Advisors LLC now owns 11,528 shares of the biopharmaceutical company's stock valued at $3,171,000 after buying an additional 3,373 shares during the period. Pallas Capital Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 61.8% in the 3rd quarter. Pallas Capital Advisors LLC now owns 3,321 shares of the biopharmaceutical company's stock valued at $975,000 after buying an additional 1,269 shares during the last quarter. Finally, New York State Teachers Retirement System acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $1,453,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 4.1 %

NASDAQ ALNY traded up $9.65 on Friday, reaching $246.75. 1,178,627 shares of the stock traded hands, compared to its average volume of 731,883. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a fifty day moving average price of $254.32 and a 200-day moving average price of $262.22. The company has a market cap of $31.94 billion, a price-to-earnings ratio of -113.71 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of the company's stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 52,592 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company's stock, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 72,986 shares of company stock valued at $20,397,849 in the last quarter. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ALNY. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Wolfe Research lowered Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. Scotiabank lowered their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating for the company in a research report on Friday, February 14th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $304.26.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.